Vincenzo Di Marzo
Laval University
709 Papers
4.8K Citations
Vincenzo Di Marzo is an academic researcher from Laval University. The author has contributed to research in topics: Endocannabinoid system & Cannabinoid receptor. The author has an hindex of 126, co-authored 659 publications. Previous affiliations of Vincenzo Di Marzo include National Research Council & University of Siena.
Chat about Author
Papers
Cannabidiol improves vocal learning-dependent recovery from, and reduces magnitude of deficits following, damage to a cortical-like brain region in a songbird pre-clinical animal model.
Ali Alalawi,Julien C. Dodu,Marie Woolley-Roberts,James Brodie,Vincenzo Di Marzo,Ken Soderstrom +5 more
TL;DR: Cannabidiol holds promise to improve functional recovery of complex learned behaviors following brain injury, and represents establishment of an important new animal model to screen drugs for efficacy to improve vocal recovery.
Allodynia Lowering Induced by Cannabinoids and Endocannabinoids (ALICE).
TL;DR: The possible modulation of the endocannabinoid system in the neuronal, glial and microglial modulation in neuropathic pain treatment is highlighted.
Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.
Fabio Arturo Iannotti,Ester Pagano,Aniello Schiano Moriello,Filomena Grazia Alvino,Nicolina Cristina Sorrentino,Luca D’Orsi,Elisabetta Gazzerro,Raffaele Capasso,Elvira De Leonibus,Luciano De Petrocellis,Vincenzo Di Marzo +10 more
TL;DR: This work explored the possibility of using non‐euphoric compounds present in Cannabis sativa, Cannabidiol (CBD), cannabidivarin (CBIV) and tetrahydrocannabidvarin (THCV) to reduce inflammation, restore functional autophagy and positively enhance muscle function in vivo.
Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice
Lynsey G. Bilsland,James R. Dick,Gareth Pryce,Stefania Petrosino,Vincenzo Di Marzo,David Baker,Linda Greensmith +6 more
TL;DR: Treatment of postsymptomatic SOD1G93A mice with a synthetic cannabinoid, WIN55,212‐2, significantly delays disease progression and cannabinoids have significant neuroprotective effects in this model of ALS and it is suggested that these beneficial effects may be mediated by non‐CB1 receptor mechanisms.